Avalo Reports 2024 Financial Results and Recent Business Updates
Provided By GlobeNewswire
Last update: Mar 20, 2025
WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024.
Read more at globenewswire.comNASDAQ:AVTX (11/20/2025, 2:26:02 PM)
17.795
+0.21 (+1.17%)
Find more stocks in the Stock Screener
